October 19, 2023

Semaglutide statement and peptide brief updated

In light of recent developments, we’ve updated our official statement on shortage drug compounding and semaglutide, as well as our Prescriber Brief on peptide compounding.

The semaglutide statement was updated to indicate that a judge has dismissed Novo’s lawsuit against one compounding pharmacy for compounding semaglutide; and also to note that Eli Lilly is suing some compounding pharmacies over tirzepatide compounding.

The peptides brief was updated to include information about certain peptides that FDA recently added to Category 2, meaning the agency could take action against pharmacies that compound those substances.